|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM063516993 |
| 003 |
DE-627 |
| 005 |
20231221223846.0 |
| 007 |
tu |
| 008 |
231221s1984 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0212.xml
|
| 035 |
|
|
|a (DE-627)NLM063516993
|
| 035 |
|
|
|a (NLM)6374684
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Mosbech, H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Controlled-release theophylline and proxyphylline in asthmatics
|b a comparative study
|
| 264 |
|
1 |
|c 1984
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.06.1984
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a In a short-term study, a new sustained-release preparation of proxyphylline (2400 mg/day) was compared to theophylline (800 mg/day) and placebo. A double-blind crossover design was used, and 10 adult asthmatics participated. No significant differences were found between the treatments with regard to relief of asthma symptoms, need for additional medication or incidence and intensity of side-effects. In the placebo period, morning peak-flow was significantly lower compared to active treatment periods
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Delayed-Action Preparations
|2 NLM
|
| 650 |
|
7 |
|a proxyphylline
|2 NLM
|
| 650 |
|
7 |
|a 13G1DMN4P0
|2 NLM
|
| 650 |
|
7 |
|a Aminophylline
|2 NLM
|
| 650 |
|
7 |
|a 27Y3KJK423
|2 NLM
|
| 650 |
|
7 |
|a Theophylline
|2 NLM
|
| 650 |
|
7 |
|a C137DTR5RG
|2 NLM
|
| 700 |
1 |
|
|a Paulsen, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Søborg, M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1984), 9 vom: 14., Seite 626-30
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:3
|g year:1984
|g number:9
|g day:14
|g pages:626-30
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 1984
|e 9
|b 14
|h 626-30
|